Objective To explore the gene expression pattern of sample of human ovarian carcimoma Method The difference in gene expression between normal and neoplastic human ovarian tissues were investigated,we described the assembly and utilization of a 512 member cDNA microarray Result Thirty seven genes expressed in ovarian cancer were screened out,14 genes were up regulated,23 genes were down regulated Conclusion cDNA microarray for analysis of gene expression pattern is an effective method to identify novel ovarian cancer associated genes

Objective To evaluate the value of human epididymis secretory protein 4(HE4)and CAl25 in the diagnosis of ovariall malignancy.Methods HF4 and CA125 in the serum specimens of malignant ovarian tumor group(30 cases),benign ovarian diseases(110 cases;45 benign ovarian tumor,57endometriotic diseases and 8 pelvic inflammation were included) and healthy women group( 137 cases)were assayed double blindly . The levels and the diagnosis efficiency of the HE4 and CA125 were analyzed.Results (1) The median levels of HE4 and CA125 were significantly higher in malignant ovarian tumor group (244 pmoi/L and 601 kU/L respectively) than those of the benign ovarian diseases group( 32 pmol/L and 22 kU/L respectively)and healthy women group (32 pmoi/L and 11 kU/L respectively) (P =0. 000-0. 029). The median levels of CA125 were also higher in endometriotic diseases and pelvic inflammation groups(53 and 41 kU/L respectively) than those of benign ovarian tumor group and healthy women group (12 and 11 kU/L respectively;P = 0. 000-0. 031 ). (2) The positive rate of HE4 was lower than that of CA12s in malignant ovarian tumor group ( P = 0. 036 ). HE4 was negative in benign diseases and healthy women groups. But the positive rates of CA125 were 56. 1% and 5/8 respectively in endometriotic diseases and pelvic inflammation groups and there were significant differences compared with HE4( P =0. 000). (3)The HE4 assay had advantage over the CA125 assay in receiver operating characteristic-area under the curve (ROC-AUC) and sensitivity with a specificity of 100% when ovarian malignancy was compared with controls having benign diseases and healthy women, benign tumor or benign diseases groups respectively. The CA125 assay had advantage over the HE4 assay in ROC-AUC and sensitivity with the same specificity when ovarian cancers were compared with controls having healthy women group. (4) Combined assay of HE4 and CA125was better than CA125 alone when ovarian malignancy was compared with controls having any group. (5)Combined assay was better than HE4 alone in ROC-AUC and sensitivity with the same specificity when ovarian cancers were compared with controls having benign diseases and healthy women or healthy women groups. And combined assay was lower in the ROC-AUC and the sensitivity with specificity of 100% than HE4 when ovarian cancers were compared with controls having benign tumors or benign diseases groups respectively. (6) The diagnosis efficiency of the HE4 assay at the level 86 pmol/L determined in ROC curve with controls having benign diseases and healthy women group and at the 95% reference level 50 pmol/L of healthy women or 150 pmol/L recommended by the kit respectively was compared. The sensitivity of 50 pmol/L was 73% higher than 150 pmol/L and 86 pmoi/L, while the specificity and positive predictive value were lower ( P = 0. 002, P = 0. 000 ). The specificity, accuracy and positive predictive value of HE4 assay at the set point of 150 pmol/L and 86 pmol/L were 100%, 96% and 96%. The set point of 86 pmol/L had advantage over 150 pmol/L at the sensitivity of diagnosis, 70% and 63% respectively. But the positive predictive value was 95% lower than 150 pmol/L, being 100%. There was no significant difference( P =0. 883, P = 0. 883 ). Conclusions The specificity of HF4 assay is higher than CA125 assay in the diagnosis of ovarian cancer and HE4 combined with CA125 assay can improve the diagnoses. The set point of 150 pmol/L is advantageous for the accurate diagnosis, while the set point of 86 pmol/L is advantageous for the screening of malignant ovarian cancer.

Objective:To summarize the best evidence of chronic pain management in the elderly, and to provide reference for the clinical practice of chronic pain management in the elderly.Methods:Focusing on the problem of chronic pain in the elderly, evidence-based nursing method was used to search the relevant literature in domestic and foreign databases from the establishment of the database to June 2, 2020. Two researchers evaluated the quality of various studies and level of evidence recommendation by the JBI evidence-based health care center's literature quality evaluation standard and evidence recommendation system, and extracted evidences from the literature meeting the inclusion criteria.Results:A total of 20 articles were included with 8 guides, 3 systematic reviews, 3 expert consensus, 1 best decision, 1 position statement and 4 evidence summaries. Finally, 20 pieces of best evidence were formed, including general principles of pain management, pain assessment, intervention strategies, self-management, education and training.Conclusions:This study summarizes the current literature on chronic pain in the elderly, which provides evidence-based basis for the management of chronic pain in the elderly. Clinicians should use the evidence according to the best clinical evidence and the actual medical conditions of the hospital, in order to improve the quality of nursing.